Newly Recognized Cutaneous Drug Eruptions

Dermatologic Clinics

Volumn 25, Issue 2, 2007, Pages 255-261

  Callen, Jeffrey P ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; ADALIMUMAB; ALPHA INTERFERON; AMFEBUTAMONE; ANTIFUNGAL AGENT; BETA INTERFERON; CALCIUM CHANNEL BLOCKING AGENT; CANERTINIB; CETUXIMAB; CINNARIZINE; DASATINIB; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; ETANERCEPT; GEFITINIB; GRISEOFULVIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMATINIB; INFLIXIMAB; LAPATINIB; LEFLUNOMIDE; MINOCYCLINE; NONSTEROID ANTIINFLAMMATORY AGENT; PELITINIB; PHENYTOIN; RAPAMYCIN; SILDENAFIL; SULFONYLUREA; TAMOXIFEN; TERBINAFINE; THIAZIDE DIURETIC AGENT; TIOTROPIUM BROMIDE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNINDEXED DRUG;

DOSE RESPONSE; DRUG ERUPTION; DRUG WITHDRAWAL; ERECTILE DYSFUNCTION; ERYTHEMA; EXFOLIATIVE DERMATITIS; FOLLICULITIS; HAND FOOT SYNDROME; HISTOPATHOLOGY; HUMAN; INJECTION SITE REACTION; LICHEN PLANUS; LICHENOID ERUPTION; MYELOID LEUKEMIA; PATHOGENESIS; PITYRIASIS ROSEA; PRIORITY JOURNAL; PUSTULOSIS; RASH; REVIEW; SKIN DISEASE; SKIN LUPUS ERYTHEMATOSUS; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS;

ANTINEOPLASTIC AGENTS; BIOLOGICAL RESPONSE MODIFIERS; DRUG ERUPTIONS; HUMANS; LUPUS ERYTHEMATOSUS, CUTANEOUS; PHOSPHODIESTERASE INHIBITORS;

EID: 34047254548     PISSN: 07338635     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.det.2007.01.003     Document Type: Review

References (37)

1. Suntharalingam G., Perry M.R., Ward S., et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 355 (2006) 1018-1028
2. Drazen J.M. Volunteers at risk. N Engl J Med 355 (2006) 1060-1061
3. Burgin S. New drugs, new rashes: update on cutaneous drug reactions. Adv Dermatol 21 (2005) 279-302
4. Perez-Soler R., Delord J.P., Halpern A., et al. HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. Oncologist 10 (2005) 345-356
5. Perez-Soler R., and Saltz L. Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining?. J Clin Oncol 23 (2005) 5235-5246
6. Agero A.L.C., Dusza S.W., Benvenuto-Andrade C., et al. Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. J Am Acad Dermatol 55 (2006) 657-670
7. Seiverling E.V., Fernandez E.M., and Adams D. Epidermal growth factor receptor (EGFR) inhibitor associated skin eruption. J Drugs Dermatol 5 (2006) 368-369
8. Laffitte E., and Saurat J.-H. Kinase inhibitor-induced pustules. Dermatology 211 (2005) 305-306
9. Roé E., Muret M.P.G., Marcuello E., et al. Description and management of cutaneous side effects during cetuximab or erlotinib treatments: a prospective study of 30 patients. J Am Acad Dermatol 55 (2006) 429-437
10. Brazzelli V., Prestinari F., Roveda E., et al. Pityriasis rosea-like eruption during treatment with imatinib mesylate: description of 3 cases. J Am Acad Dermatol 53 5 Suppl 1 (2005) S240-S243
11. Dalmau J., Peramiquel L., Puig L., et al. Imatinib-associated lichenoid eruption: acitretin treatment allows maintained antineoplastic effect. Br J Dermatol 154 (2006) 1213-1216
12. Ayirookuzhi S.J., Ma L., Ramshesh P., et al. Imatinib-induced sweet syndrome in a patient with chronic myeloid leukemia. Arch Dermatol 141 (2005) 368-370
13. Assouline S., Laneuville P., and Gambacorti-Passerini C. Panniculitis during dasatinib therapy for chronic myelogenous leukemia. N Engl J Med 354 (2006) 2623-2624
14. Thielen A.M., Kuenzli S., and Saurat J.-H. Cutaneous adverse events of biological therapy for psoriasis: review of the literature. Dermatology 211 (2005) 209-217
15. Kary S., Worm M., Audring H., et al. New onset or exacerbation of psoriatic skin lesions in patients with definite rheumatoid arthritis receiving tumour necrosis factor alpha antagonists. Ann Rheum Dis 65 (2006) 405-407
16. de Gannes GC, Ghoreishi M, Pope J, et al. Psoriasis and pustular dermatitis triggered by tumor necrosis factor-α inhibitors in patients with rheumatologic conditions. Arch Dermatol, in press.
17. Urbani R, Van Voorhees AS. Onset of psoriasis during treatment with tumor necrosis factor-alpha antogonists: three cases. Arch Dermatol, in press.
18. Pirard D., Arco D., Debrouckere V., et al. Anti-tumor necrosis factor alpha-induced psoriasiform eruptions: three further cases and current overview. Dermatology 213 (2006) 182-186
19. Fiorentino DF. The Yin and Yang of TNF-α inhibition. Arch Dermatol, in press.
20. Bleumink G.S., ter Borg E.J., Ramselaar C.G., et al. Etanercept-induced subacute cutaneous lupus erythematosus. Rheumatology 40 (2001) 1317-1319
21. Fautrel B., Foltz V., Frances C., et al. Regression of subacute cutaneous lupus erythematosus in a patient with rheumatoid arthritis treated with a biologic tumor necrosis factor alpha-blocking agent: comment on the article by Pisetsky and the letter from Aringer et al. Arthritis Rheum 46 5 (2002) 1408-1409
22. Norman R., Greenberg R.G., and Jackson J.M. Case reports of etanercept in inflammatory dermatoses. J Am Acad Dermatol 54 3 Suppl 2 (2006) S139-S142
23. Winfield H., Lain E., Horn T., et al. Eosinophilic cellulitislike reaction to subcutaneous etanercept injection. Arch Dermatol 142 (2006) 218-220
24. Boura P., Sarantopoulos A., Lefaki I., et al. Eosinophilic cellutlitis (Well's syndrome) as a cutaneous reaction to the administration of adalimumab. Ann Rheum Dis 65 (2006) 839-840
25. Antiga E., Melani L., Cardinali C., et al. A case of lichenoid drug eruption associated with sildenafil citrates. J Dermatol 32 (2005) 972-975
26. Al-Shouli S., Abouchala N., Bogusz M.J., et al. Toxic epidermal necrolysis associated with high intake of sildenafil and its response to infliximab. Acta Derm Venereol 85 (2006) 534-535
27. Mahé E., Morelon E., Lechaton S., et al. Acne in recipients of renal transplantation treated with sirolimus: clinical, microbiologic, histologic, therapeutic, and pathogenic aspects. J Am Acad Dermatol 55 (2006) 139-142
28. Mahé E., Morelon E., Lechaton S., et al. Cutaneous adverse events in renal transplant recipients receiving sirolimus-based therapy. Transplantation 79 (2005) 476-482
29. Reed B.R., Huff J.C., Jones S.K., et al. Subacute cutaneous lupus erythematosus associated with hydrochlorothiazide therapy. Ann Intern Med 103 1 (1985) 49-51
30. Srivastava M., Rencic A., Diglio G., et al. Drug-induced, Ro/SSA-positive cutaneous lupus erythematosus. Arch Dermatol 139 (2003) 45-49
31. Porter D., and Harrison A. Minocycline-induced lupus: a case series. N Z Med J 116 1171 (2003) U384
32. Cassis T.B., and Callen J.P. Bupropion-induced subacute cutaneous lupus erythematosus. Australas J Dermatol 46 (2005) 266-269
33. Farhi D., Viguier M., Cosnes A., et al. Terbinafine-induced subacute cutaneous lupus erythematosus. Dermatology 212 (2006) 59-65
34. Rothfield N., Sontheimer R.D., and Bernstein M. Lupus erythematosus: systemic and cutaneous manifestations. Clin Dermatol 24 (2006) 348-362
35. Callen J.P. How frequently are drugs associated with the development or exacerbation of subacute cutaneous lupus?. Arch Dermatol 139 1 (2003) 89-90
36. Ke C.-L., Chen C.-C., Lin C.-T., et al. Fluvoxamine-induced bullous eruption mimicking hand-foot syndrome and intertrigo-like eruption: rare cutaneous presentations and elusive pathogenesis. J Am Acad Dermatol 55 (2006) 355-356
37. Chung N.M., Guiterrez M., and Turner M.L. Leukocytoclastic vasculitis masquerading as hand foot syndrome in a patient on Bay 43-9006. Arch Dermatol 142 (2006) 1510-1511